Skip to main content
OpenTrials
Completed

NCT Number: NCT01077648

Brain Metastasis in Breast Cancer Patients

The purpose of this epidemiologic study is to establish a population-based cohort of women with advanced stage breast cancer which can be used to quantify the frequency and timing of brain metastases, and other distant metastases, in this patient population.

Completed

Looking for future studies?

Notify Me

Key information

About this study

A retrospective cohort study will be conducted in the Henry Ford Health System (HFHS). Using medical record review, we will identify all women diagnosed with advanced stage (stage III and IV) breast cancer between January 1, 1995- December 31, 2007. For each case included in the study, we will obtain data on demographics, tumor information, treatment related medical encounters and procedures, and occurrence and timing of brain and/or other distant metastases. The main outcome for this study is the development of distant metastases. Each patient in the cohort will be classified as to the occurrence and date of distant metastases. Metastases will be classified as Brain, Distant lymph node, Lung/pleural effusion, Liver, Bone, Other visceral, Other non-visceral.

Other secondary outcomes to be explored include:

  • Survival after advanced breast cancer-time in months from the date of advanced stage breast cancer diagnosis until death or end of study period
  • Time to brain metastases-time in month from the date of advanced stage breast cancer diagnosis until brain metastases diagnosis
  • Survival after brain metastases-time in months from the date of diagnosis of brain metastases until death or end of study period

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Initially diagnosed with American Joint Commission on Cancer (AJCC) stage III or stage IV breast cancer between January 1, 1995 through December 31, 2007 -OR- diagnosed with AJCC stage I or II breast cancer and progressed to stage III or IV disease between January 1, 1995 through December 31, 2007;
  • At least one year of follow-up after initial diagnosis (among patients who did not die before one year of follow-up); and
  • Age 30 years or older at diagnosis.

Exclusion criteria

  • Does not have at least one year of follow-up after initial diagnosis (among patients who did not die before one year of follow-up); and
  • Age less than 30 years or older at diagnosis.

Treatment and study plan

Trastuzumab or Lapatinib

Drug

Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.

Primary outcomes

  1. Proportion of advanced stage breast cancer patients that develop brain metastases, overall and stratified by anti-HER2 therapy (for HER2+ patients only).

    Time frame: Time from breast cancer diagnosis until death or end of study periods (September 1, 2009)

Secondary outcomes

  1. Overall survival from advanced stage breast cancer, overall and stratified by tumor characteristics and anti-HER2 therapy (for HER2+ patients only).

    Time frame: Time from diagnosis of advanced stage breast cancer until death or end of study period (September 1, 2009)

  2. Time to brain metastases stratified by key tumor characteristics and anti-HER2 therapy (for HER2+ patients only).

    Time frame: Time from diagnosis of advanced stage breast cancer until brain metastases diagnosis

  3. Survival after brain metastases diagnosis, overall and stratified by key tumor characteristics and anti-HER2 therapy (for HER2+ patients only)

    Time frame: Time from diagnosis of brain metastases until death or end of study period (September 1, 2009)

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Occurrence of Brain Metastasis in Breast Cancer Patients Diagnosed at Advanced Stages of the Disease

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
Mar 1, 2010
Registry last updated
May 26, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.